Memory Pharmaceuticals Corp. plans to conduct a clinical study of MEM 3454, the company’s lead nicotinic alpha-7 partial agonist, in patients with schizophrenia based on two biomarkers, P50 sensory gating and mismatch negativity. Development partner, Roche, will fund the biomarker study and additional formulation and manufacturing activities for MEM 3454 under the companies’ development collaboration for nicotinic alpha-7 receptor agonists.     “This new study will greatly e...